Biomarkers for early detection of sickle nephropathy

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 559-566

  Sundaram, Nambirajan ^a   Bennett, Michael ^a   Wilhelm, Jamie ^a   Kim, Mi Ok ^a   Atweh, George ^a   Devarajan, Prasad ^a   Malik, Punam ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALBUMINURIA; ARTICLE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OSMOLALITY; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; SICKLE NEPHROPATHY; STEADY STATE;

ACETYLGLUCOSAMINIDASE; ACUTE-PHASE PROTEINS; ADOLESCENT; ALBUMINURIA; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CREATININE; CROSS-SECTIONAL STUDIES; CYSTATIN C; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS;

EID: 79959343341     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22045     Document Type: Article

References (47)

1. Pham PT, Pham PC, Wilkinson AH, et al. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57: 1-8.
2. de Santis Feltran L, de Abreu Carvalhaes JT, Sesso R. Renal complications of sickle cell disease: Managing for optimal outcomes. Paediatr Drugs 2002; 4: 29-36.
3. Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992; 326: 910-915.
4. Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann Intern Med 1991; 115: 614-620.
5. Hiti AL, Zeng L, Xiang Q, et al. Beta-globin haplotypes from blood spots for follow-up of newborn hemoglobinopathy screening. 1997; 54: 76-78.
6. Bakir AA, Hathiwala SC, Ainis H, et al. Prognosis of the nephrotic syndrome in sickle glomerulopathy. A retrospective study. Am J Nephrol 1987; 7: 110-115.
7. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol 2000; 63: 205-211.
8. Wesson DE. The initiation and progression of sickle cell nephropathy. Kidney Int 2002; 61: 2277-2286.
9. Alvarez O, Zilleruelo G, Wright D, et al. Serum cystatin C levels in children with sickle cell disease. Pediatr Nephrol 2006; 21: 533-537.
10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
11. Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010; 5: 2154-2165.
12. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28: 478-485.
13. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010; 28: 436-440.
14. Hoffmann D, Adler M, Vaidya VS, et al. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci 2010; 116: 8-22.
15. Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagnostics 2008; 2: 387-398.
16. Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010; 15: 419-428.
17. Voskaridou E, Terpos E, Michail S, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int 2006; 69: 2037-2042.
18. Mohtat D, Thomas R, Du Z, et al. Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. Pediatr Nephrol 2011; 26: 275-280.
19. Foucan L, Bourhis V, Bangou J, et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med 1998; 104: 339-342.
20. Guasch A, Cua M, Mitch WE. Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int 1996; 49: 786-791.
21. Guasch A, Navarrete J, Nass K, et al. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 2006; 17: 2228-2235.
22. Guasch A, Zayas CF, Eckman JR, et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol 1999; 10: 1014-1019.
23. Guasch A, Cua M, You W, et al. Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Kidney Int 1997; 51: 826-833.
24. Wigfall DR, Ware RE, Burchinal MR, et al. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr 2000; 136: 749-753.
25. Dharnidharka VR, Dabbagh S, Atiyeh B, et al. Prevalence of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 1998; 12: 475-478.
26. McBurney PG, Hanevold CD, Hernandez CM, et al. Risk factors for microalbuminuria in children with sickle cell anemia. J Pediatr Hematol Oncol 2002; 24: 473-477.
27. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18: 1353-1361.
28. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. New England J Med 2003; 348: 2285-2293.
29. Ataga KI, Brittain JE, Moore D, et al. Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: Potential role of soluble fms-like tyrosine kinase-1. Eur J Haematol 2010; 85: 257-263.
30. Miller ST, Wang WC, Iyer R, et al. Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatric Blood Cancer 2010; 54: 265-268.
31. Francis YF, Worthen HG. Hyposthenuria in sickle cell disease. J Natl Med Assoc 1968; 60: 266-270.
32. Gupta AK, Kirchner KA, Nicholson R, et al. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest 1991; 88: 1963-1968.
33. Itano HA, Keitel HG, Thompson D. Hyposthenuria in sickle cell anemia: A reversible renal defect. J Clin Invest 1956; 35: 998-1007.
34. Statius van Eps LW, Schouten H, La Porte-Wijsman LW, et al. The influence of red blood cell transfusions on the hyposthenuria and renal hemodynamics of sickle cell anemia. Clin Chim Acta 1967; 17: 449-461.
35. Iyer R, Baliga R, Nagel RL, et al. Maximum urine concentrating ability in children with Hb SC disease: Effects of hydroxyurea. Am J Hematol 2000; 64: 47-52.
36. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: Baseline data from the BABY HUG trial. J Pediatr 2010; 156: 66-70 e61.
37. Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int 2011; 79: 464-470.
38. Grenda R, Wuhl E, Litwin M, et al. Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: Results of the ESCAPE trial. Nephrol Dial Transplant 2007; 22: 3487-3494.
39. De Muro P, Faedda R, Fresu P, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res 2004; 49: 293-298.
40. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nature Gene 2005; 37: 435-440.
41. Elliott L, Ashley-Koch AE, De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007; 137: 262-267.
42. Fertrin KY, Costa FF. Genomic polymorphisms in sickle cell disease: Implications for clinical diversity and treatment. Expert Rev Hematol 2010; 3: 443-458.
43. Ashley-Koch AE, Elliott L, Kail ME, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 2008; 111: 5721-5726.
44. Nolan VG, Ma Q, Cohen HT, et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. Am J Hematol 2007; 82: 179-184.
45. Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011; 23: 194-200.
46. Vaidya VS, Ford GM, Waikar, et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76: 8-10.
47. Marsenic O, Couloures KG, Wiley JM. Proteinuria in children with sickle cell disease. Nephrol Dial Transplant 2008; 23: 715-720.